Hormone Therapy Linked to Lower Heart Disease Risk
A new study reveals that starting hormone therapy early in menopause may reduce cardiovascular events for some women.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Do you trust that starting hormone therapy during menopause reduces your long-term heart disease risk?
Researchers have found that initiating menopausal hormone therapy correlates with a reduced risk of cardiovascular disease. The analysis showed an adjusted hazard ratio of 0.78 for those undergoing the therapy.
Why it matters
The findings suggest that the timing of hormone therapy plays a critical role in cardiovascular health outcomes for women during menopause. Identifying these patterns helps clarify how clinical interventions can mitigate heart disease risk in this population.
The study recorded 224 fatal and nonfatal cardiovascular events among participants. Results showed a hazard ratio of 0.73 for those initiating therapy within 10 years of menopause, compared to 1.53 for those starting after 10 years.
The players
University of Pittsburgh School of Public Health
This academic institution is a center for research and training in public health and serves as the affiliation for the study's lead author.
Study of Women's Health Across the Nation
This is a long-term, multi-site epidemiological study that examines the health and menopausal transition of women.
The details
Researchers analyzed cohort data from the Study of Women's Health Across the Nation to evaluate the impact of hormone therapy initiation on cardiovascular health. The study noted a particularly strong association for Black women, who saw an adjusted hazard ratio of 0.51.
Timeline
The study analyzed cohort data collected between 1997 and 2017.
The research findings were published on September 8, 2026.
The Big Picture
This research utilizes the Study of Women's Health Across the Nation to provide a longitudinal framework for understanding menopausal health transitions. It extends existing data from this program by isolating the relationship between hormone therapy timing and long-term cardiovascular outcomes.
The findings underscore the importance of discussing the timing of hormone therapy with a healthcare provider to manage individual cardiovascular risk. Patients should be aware that benefits may vary significantly depending on how many years have passed since the onset of menopause.
The takeaway
This study highlights that the window of opportunity for hormone therapy in menopause may be narrow regarding cardiovascular protection. Consulting with a physician to evaluate personal risk factors remains the most effective way to navigate these treatment options.
Further reading
Learn more about the latest research and clinical guidelines in our Heart Disease section.
Live Poll
Do you trust that starting hormone therapy during menopause reduces your long-term heart disease risk?
